Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers - OncLive
6/7/2022 12:00:00 AM2 years 11 months ago
by Nichole Tucker
by Nichole Tucker
Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an…
Treatment with larotrectinib (Vitrakvi) led to early onset and clinically meaningful improvements in health-related quality of life (HRQoL) that were sustained for more than 12 months in most adult a… [+6358 chars]
full article...